权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Innate and Adaptive Immunity in Parkinson Disease

帕金森病的先天性和适应性免疫

基本信息

批准号：
9085428
负责人：
DAVID G. STANDAERT
金额：
$ 32.08万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-01 至 2018-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9085428
关键词：
Anxiety Basic Science Biological Models Bradykinesia Brain CD4 Positive T Lymphocytes Clinical Collaborations Communities Community Outreach Complement Data Dementia Development Disease Disease Progression Education and Outreach Elements Environment Fostering Functional disorder Future Gap Junctions Goals Grant HLA-DR Antigens Immune system Immunoglobulins Impaired cognition Infiltration Inflammatory LRRK2 gene Lead Ligands Mediation Mental Depression Mus Myeloid Cell Activation Myeloid Cells National Institute of Neurological Disorders and Stroke Natural Immunity Nature Neurodegenerative Disorders Parkinson Disease Pathogenesis Pathway interactions Pharmaceutical Preparations Phase Population Positron-Emission Tomography Pre-Clinical Model Predisposition Process Production Proteins Recommendation Reporting Research Personnel Resources Risk Factors Role Signal Transduction Sleep Disorders Staging Substantia nigra structure Symptoms TNFRSF5 gene Testing Therapeutic Tissues Tremor Vision adaptive immunity alpha synuclein base chemokine cytokine equilibration disorder gastrointestinal genome wide association study human disease human subject member motor symptom neuroimmunology neuroinflammation neuron loss neuroprotection non-motor symptom novel pars compacta perineural pre-clinical programs public health relevance restoration success symposium targeted treatment urinary

项目摘要

DESCRIPTION (provided by applicant): The development of neuroprotective strategies for PD is a vital unmet need. Despite remarkable advances in the last fifteen years in the understanding of pathobiological mechanisms in PD, there are no known therapies available that slow the progression or alter the course of PD. The systemic nature of PD suggests new pre-clinical approaches are needed in order to identify pathways and associated therapeutics that might slow the progression of disease. As stated in the Conference and Recommendations Report to NINDS Council (PD2014), "the community of investigators focused on PD now strives to create therapies that meaningfully slow or stop the disease mechanisms that underlie all symptoms of PD". Neuroinflammation is increasingly recognized as a critically important element of PD pathogenesis. The vision for this P20 Exploratory Grant is to create the team, environment, and capability to explore innate and adaptive immunity in PD. Currently, there are no Udall Centers of Excellence that focus on understanding neuroinflammatory mechanisms in PD. These studies will require a team with a combination of specialized expertise in neuroimmunology and neurodegenerative disorders. We request support to foster the development of new collaborations and to develop critical data both in PD subjects as well as in recently developed pre-clinical models of PD. The investigative team includes two established investigators in PD (Drs. David Standaert and Andrew West), and an established investigator from the field of neuroimmunology (Dr. Etty "Tika" Benveniste). We will explore neuro-inflammatory signaling, particularly the actions of myeloid cells, in pre-clinical models of PD as well as early human disease. It is expected that success in these exploratory studies will lead to the development of a future Udall Center of Excellence dedicated to understanding the roles of the innate and adaptive immune system in PD, with emphasis on pursuing points of therapeutic mediation and novel neuroprotection strategies.